{"id":100018,"date":"2025-10-16T18:34:07","date_gmt":"2025-10-16T18:34:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/global-anti-parkinsons-drugs-markets-projected-to-reach-9-2-billion-by-the-end-of-2030\/"},"modified":"2025-10-16T18:34:07","modified_gmt":"2025-10-16T18:34:07","slug":"global-anti-parkinsons-drugs-markets-projected-to-reach-9-2-billion-by-the-end-of-2030","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/global-anti-parkinsons-drugs-markets-projected-to-reach-9-2-billion-by-the-end-of-2030\/","title":{"rendered":"Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030"},"content":{"rendered":"
\n

Boston, Oct. 16, 2025 (GLOBE NEWSWIRE) — According to the latest study from BCC Research, \u201cAnti-Parkinson’s Drugs: Global Markets to 2030<\/b><\/a>\u201d is projected to grow from $6.1 billion in 2025 to $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.<\/p>\n

The report provides a detailed analysis of the global anti-Parkinson\u2019s drugs market, highlighting trends, growth projections, and regional insights. It segments the market by drug class, including dopaminergic agents, dopamine agonists, COMT inhibitors, MAO-B inhibitors, anticholinergics, and others. It covers the regions of North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, and also focuses on the major countries in each. Additionally, it explores ESG developments, emerging technologies, and the competitive landscape, including company profiles and recent developments.<\/p>\n

This report is especially relevant right now due to the rising global prevalence of Parkinson\u2019s disease and the urgent need for more effective treatments. With no curative therapies currently available, there is a significant unmet medical need driving increased research and innovation in this field. The report captures this momentum by analyzing market trends, emerging technologies, and investment activities, making it a timely resource for stakeholders looking to understand and engage with the evolving landscape of anti-Parkinson\u2019s drug development.<\/p>\n

The factors driving the market\u2019s growth include:<\/b><\/p>\n

Growing prevalence of Parkinson\u2019s disease: <\/b>The global rise in P cases of parkinson\u2019s, especially among aging populations, is significantly increasing the demand for treatments. With millions already affected and numbers expected to grow, the market for anti-Parkinson\u2019s drugs is expanding rapidly.<\/p>\n

High unmet need: <\/b>Current therapies mainly manage symptoms without slowing the disease\u2019s progression, leaving a large gap in treatment. Patients often face motor complications and non-motor symptoms that are not well addressed, highlighting the need for more advanced and comprehensive solutions.<\/p>\n

Strategic initiatives<\/b>: Pharmaceutical companies are launching new drugs, forming partnerships, and acquiring biotech firms to strengthen their portfolios. These strategic moves are accelerating innovation and expanding access to better therapies for Parkinson\u2019s patients.<\/p>\n

Public and private investments and support: <\/b>Significant funding from government bodies and foundations is fueling R&D in Parkinson\u2019s treatment. These investments support clinical trials, drug discovery, and awareness programs, helping to drive market growth.<\/p>\n

Robust pipeline:<\/b> A strong pipeline of innovative therapies, including gene therapies, RNA-based drugs, and advanced delivery systems, is poised to transform Parkinson\u2019s care. These developments aim to offer more effective, personalized, and long-lasting treatment options.<\/p>\n

Request a sample copy of <\/b>the anti-Parkinson\u2019s drugs report<\/b><\/a>.<\/b><\/p>\n

Report Synopsis<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Report Metric<\/b><\/td>\nDetails<\/b><\/td>\n<\/tr>\n
Base year considered<\/td>\n2024<\/td>\n<\/tr>\n
Forecast period considered<\/td>\n2025-2030<\/td>\n<\/tr>\n
Base year market size<\/td>\n$5.6 billion<\/td>\n<\/tr>\n
Market size forecast<\/td>\n$9.2 billion<\/td>\n<\/tr>\n
Growth rate<\/td>\nCAGR of 8.6% from 2025 to 2030<\/td>\n<\/tr>\n
Segments covered<\/td>\nDrug Class (based on Mechanism of Action) and Region<\/td>\n<\/tr>\n
Regions covered<\/td>\nNorth America, Europe, Asia-Pacific and the Rest of the World (RoW)<\/td>\n<\/tr>\n
Countries covered<\/td>\nU.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Rest of Europe, China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific<\/td>\n<\/tr>\n
Market drivers<\/td>\n\n